Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

Antibe Therapeutics Inc(Pre-Merger) > Waiting for the news release
View:
Post by Duster340 on Nov 06, 2023 1:15pm

Waiting for the news release

will it be on wednesday again? and then earnings report next week. i do not thing there will be much more upside before some profit taking, maybe a small pop this week after the news and then i think there will be some selling. i am a little nervous about the earnings report, maybe a surprise on raising money bought deal or reverse split. this is when investors usually get hit with dillution is when a stock moves higher, perfect opportunity for the company to raise cash for sure they will want to do it before P2 results in case of another set back which would be the end of antibe. however if they are cashed up they survive and can move on to there next drug and continue to collect a pay-cheque. i got a itchy sell finger lol
glta
Comment by InTheKnight on Nov 06, 2023 4:20pm
On the contrary, I think it will continue to run up and will surpass previous highs since the new formulation is significantly de-risked. You're already seeing some institutional buying as they are coming back for a second run. My itchy buy fingers will buy your shares if you want.  lol. Good luck to all and let's ride this wave to the bank. 
Comment by MrMugsy on Nov 06, 2023 5:56pm
Well ... if DILIsym means anything ... sure looks like it's derisked ... and ... with 15+ years patent life. DILIsym to help create a chronic path - with greater confidence now. Just give me a new molecule by mid-November and I'll be quite content. Where I wanted to be in 2023 - but - expected the Nuance ordeal to be over by now.  Fingers crossed !!!
Comment by Harper75 on Nov 07, 2023 1:44am
Are you thinking there may be a surprise Christmas present tackling both acute and chronic??  Could that be possible at this late stage...???
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities